Keytruda® (pembrolizumab) – New indication
June 17, 2020 - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) (≥ 10 mutations/megabase [mut/Mb]) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Top